OrbiMed’s Alto Neuroscience ANRO Stock Holding History

OrbiMed’s Portfolio ANRO Stock Details ANRO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$6.8M	Buy	257,852 +90,352	+54%	+$2.09M	0.13%	93
2026 Q1	$3.77M	Buy	167,500 +42,500	+34%	+$788K	0.07%	98
2025 Q4	$2.23M	Sell	125,000 -125,000	-50%	-$1.57M	0.05%	98
2025 Q3	$1M	Hold	250,000	–	–	0.02%	103
2025 Q2	$550K	Hold	250,000	–	–	0.01%	96
2025 Q1	$540K	Hold	250,000	–	–	0.01%	107
2024 Q4	$1.06M	Buy	+250,000	New	+$1.56M	0.02%	111

Other funds holding ANRO

AWG

Alpha Wave Global New York $6.24B AUM 59.73% 1-Year Est. Return

Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

SSC

Spruce Street Capital New York $510M AUM

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

OrbiMed's ANRO Position: Q2 2026 in Review

OrbiMed increased its Alto Neuroscience (ANRO) stake by 54% in Q2 2026, buying an estimated $2.09M and bringing the position to 257,852 shares worth $6.8M. The position accounts for 0.13% of the portfolio, ranked #93.

OrbiMed first reported a position in ANRO in Q4 2024 and has held it in 7 quarters since. 114 funds tracked by Wall St. Rank hold ANRO as of Q2 2026.

OrbiMed held 257,852 shares of Alto Neuroscience worth $6.8M as of Q2 2026.
OrbiMed bought 90,352 Alto Neuroscience shares in Q2 2026, an estimated $2.09M.
Alto Neuroscience made up 0.13% of OrbiMed's portfolio in Q2 2026, its #93 holding.
OrbiMed first reported a position in Alto Neuroscience in Q4 2024 and has held it in 7 quarters since.
114 funds tracked by Wall St. Rank held Alto Neuroscience as of Q2 2026.

Based on OrbiMed's 13F filing for Q2 2026, filed 14 Aug 2026.